Genzyme drops Sepracoat in US after FDA vote:
This article was originally published in Clinica
Genzyme is to discontinue the development of Sepracoat, its coating solution, in the US, resulting in write-off of around $5 million. In May 1997 the FDA voted against granting approval for the product, which is designed to reduce adhesion formation resulting from indirect trauma during surgery. The product has been CE-marked since 1996. The US company maintains the action will have no impact on the manufacture and sales of related product, Seprafilm, its surgical adhesion preventative, which received FDA approval in mid-1996.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.